Heterozygous Individuals for AGXT and Kidney Stones
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jun 10, 2020
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a specific genetic change (called a heterozygous mutation) in the AGXT gene affects the production of oxalate in people who have a history of kidney stones. If you join this study, you will follow a special low-oxalate diet for five days and provide blood and urine samples to check the levels of oxalate in your body. After that, you will receive an intravenous (IV) infusion of glycolate, and more samples will be collected to see how this affects your oxalate levels.
To participate in this trial, you need to be at least 18 years old, have a history of calcium oxalate kidney stones, and have the specific AGXT gene mutation confirmed by a genetic test. Unfortunately, the study cannot include pregnant or breastfeeding individuals. This research aims to better understand how genetics influence kidney stone formation, which could lead to improved treatments in the future. The study is not yet recruiting participants, but it is an important step in learning more about kidney stones and their causes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • at least 18 years of age
- • history of calcium oxalate stones
- • heterozygous mutation of the AGXT gene, as evidenced by results from the Invitae Nephrolithiasis Panel
- • willingness to comply with a controlled diet for five days
- Exclusion Criteria:
- • pregnant individuals
- • individuals who are currently breast feeding
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Kyle Wood, MD
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials